Tremfya (guselkumab) / J&J, Otsuka, Royalty, Taiho - LARVOL DELTA

EFFICACY AND SAFETY OF GUSELKUMAB IN PERIANAL FISTULIZING CROHN'S DISEASE: WEEK 48 RESULTS FROM THE PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED FUZION TRIAL (UEGW 2026) - No abstract available

Clinical • Late-breaking abstract • P3 data • Crohn's disease • Gastroenterology • Immunology • Inflammatory Bowel Disease

REAL-WORLD EFFECTIVENESS AND SAFETY OF GUSELKUMAB INDUCTION THERAPY IN MODERATE-TO-SEVERE CROHN' S DISEASE: A MULTICENTER COHORT STUDY IN CHINA (UEGW 2026) - No abstract available

Clinical • Late-breaking abstract • Real-world • Real-world effectiveness • Real-world evidence • Crohn's disease • Gastroenterology • Immunology

Guselkumab Versus Risankizumab for Ulcerative Colitis: Real-World Comparison of Post-Induction Outcomes. (PubMed, Clin Gastroenterol Hepatol) - No abstract available

Journal • Real-world evidence • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease • Ulcerative Colitis

Biomarker-Driven Insights From the Phase 2a AFFINITY Study Evaluating Guselkumab + Golimumab Combination Therapy Versus Guselkumab Monotherapy in Psoriatic Arthritis (ACR Convergence 2026) - P2 | "GUS+GOL CT was associated with significant reductions in CRP and IL-6 levels from BL. Pts with ACR50 and MDA responses to CT had higher BL levels of CRP and IL-6, and greater reductions in these inflammatory biomarkers over time, than nonresponders. These results support clinical findings that pts with TNFi-IR PsA may derive greater improvement in joint manifestations with GUS+GOL CT, especially in pts with elevated systemic inflammatory burden."

Biomarker • Combination therapy • Monotherapy • P2a data • Immunology • Inflammatory Arthritis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies • IL17A • IL6

Patient-Reported Outcomes in Participants With Active and Erosive Psoriatic Arthritis Receiving Guselkumab: Results Through Week 48 of a Phase 3b, Randomized Double-Blind, Placebo-Controlled Study (ACR Convergence 2026) - No abstract available

Clinical • P3 data • Patient reported outcomes • Immunology • Inflammatory Arthritis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies

Guselkumab Efficacy on Improvements in American College of Rheumatology Response Components and Association With Structural Damage Progression in Participants With Active and Erosive Psoriatic Arthritis: Results From a Phase 3b, Randomized Double-Blind, Placebo-Controlled Study (ACR Convergence 2026) - No abstract available

Clinical • P3 data • Immunology • Inflammatory Arthritis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies

Real-World On-Label Treatment Persistence Through 24 Months in Biologic-Naïve and Biologic-Experienced Patients With Psoriatic Arthritis: Comparison of Guselkumab Versus Targeted Synthetic Disease-Modifying Antirheumatic Drugs (ACR Convergence 2026) - No abstract available

Clinical • Real-world • Real-world evidence • Immunology • Inflammatory Arthritis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies

Patient-Level Persistence of On-Treatment Remission with Guselkumab: Pooled Results from VOYAGE 1 and VOYAGE 2 Participants with Moderate-to-Severe Plaque Psoriasis (ACR Convergence 2026) - No abstract available

Clinical • Dermatology • Immunology • Plaque Psoriasis • Psoriasis

Site-Specific Mucosal Candidiasis Associated With Bimekizumab, Secukinumab, and Guselkumab: A Pharmacosurveillance Analysis of the FDA Adverse Event Reporting System (FAERS) (ACR Convergence 2026) - No abstract available

Adverse events • Candidiasis

Safety of Guselkumab in Participants With Active Psoriatic Arthritis: Pooled Results From Four Phase 3, Randomized, Placebo-Controlled Trials (ACR Convergence 2026) - No abstract available

Clinical • P3 data • Immunology • Inflammatory Arthritis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies

Achievement of DAPSA/cDAPSA Low Disease Activity With Guselkumab in Active and Erosive Psoriatic Arthritis Across Participant Subgroups in APEX (ACR Convergence 2026) - No abstract available

Immunology • Inflammatory Arthritis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies

Guselkumab Response and Inhibition of Structural Damage Progression in Active Psoriatic Arthritis Across APEX Participant Subgroups (ACR Convergence 2026) - No abstract available

Immunology • Inflammatory Arthritis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies

Efficacy and Safety of Guselkumab in Participants With Active Psoriatic Arthritis and Inadequate Response/Intolerance to One Prior Tumor Necrosis Factor Inhibitor Through 1 Year of the SOLSTICE Study (ACR Convergence 2026) - No abstract available

Clinical • Immunology • Inflammatory Arthritis • Oncology • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies

Treatment Persistence and Effectiveness Across PsA Patient Subgroups Treated with Guselkumab and IL-17 Inhibitors: 12-Month Findings from the Global PsABIOnd Study (ACR Convergence 2026) - No abstract available

Clinical • Ankylosing Spondylitis • Immunology • Psoriasis • Psoriatic Arthritis • Rheumatology • Spondylarthritis • IL17A

Minimal Disease Activity at 12 Months with Guselkumab and IL-17 Inhibitors in Psoriatic Arthritis: Results from the Global PsABIOnd Study (ACR Convergence 2026) - No abstract available

Clinical • Immunology • Inflammatory Arthritis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies • IL17A

Baseline Characteristics and 12-Month Effectiveness of Guselkumab and IL-17 Inhibitors Among Participants with Oligoarticular Psoriatic Arthritis in the Global PsABIOnd Study (ACR Convergence 2026) - No abstract available

Clinical • Immunology • Inflammatory Arthritis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies • IL17A

Persistence, Effectiveness, Safety, and Patient Reported Impact of Guselkumab and IL-17 Inhibitors in Psoriatic Arthritis: Full Population Results of the PsABIOnd Global Observational Study Over 12 Months (ACR Convergence 2026) - No abstract available

Clinical • Observational data • Immunology • Inflammatory Arthritis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies • IL17A

Effectiveness of Guselkumab vs Golimumab in Participants with Active Psoriatic Arthritis and Inadequate Response to One Prior Tumor Necrosis Factor Inhibitor: Interim Results at 6 Months in a Phase 3b, Randomized, Open-Label, Pragmatic Trial (ACR Convergence 2026) - No abstract available

Clinical • P3 data • P3 data: top line • Immunology • Inflammatory Arthritis • Oncology • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies

Advanced Therapies in IBD: Biologics and Beyond (IASGO 2026) - "Ulcerative colitis: For moderate-to-severe UC, biologic options include anti-TNF agents (infliximab, adalimumab,and golimumab), vedolizumab, ustekinumab, and selective IL-23 inhibitors (mirikizumab,risankizumab, and guselkumab). Small-molecule therapies, including JAK inhibitors (tofacitiniband upadacitinib) and S1P receptor modulators (ozanimod and etrasimod), further expandtherapeutic options...Recent AGA guidance further incorporates newer IL-23inhibitors, including mirikizumab and guselkumab, and upadacitinib into the expandingtherapeutic armamentarium. Overall, contemporary IBD management is shifting from rigid treatment algorithms toward early,individualized selection of advanced therapies, integrating efficacy, safety, disease phenotype, priortreatment exposure, and patient preference."

Metastases • Crohn's disease • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease • Ulcerative Colitis • IL23A

Prevalence and clinical relevance of anti-drug antibodies in psoriatic arthritis: a systematic review. (PubMed, RMD Open) - "ADA prevalence in PsA varies widely between bDMARDs and across studies of the same bDMARD. ADAs appear most clinically relevant for TNF inhibitors, whereas evidence for other biological classes remains limited. Immunoassay heterogeneity limits comparability, highlighting the need for standardised prospective studies."

Journal • Review • Immunology • Inflammatory Arthritis • Oncology • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies • IL12A • IL23A

Early Experience With Etrasimod in Ulcerative Colitis Patients: A Claims Database Study in the United States (ACG 2026) - "(e)Advanced treatments: adalimumab, golimumab, infliximab, vedolizumab, ustekinumab, mirikizumab, risankizumab, guselkumab, tofacitinib, upadacitinib, and ozanimod. A total of 297 patients were included (mean age, 47.3 years [SD, 17.5]; 52.2% male), and 127 comprised the follow-up population. In the follow-up population, most patients were AT-naïve (67.7%), and 48.0% had used steroids within 24 weeks prior to index date (Table 1). Through week 24, median adherence was 89.8% (quartile 1: 53.9%; quartile 3: 98.8%), and 59.1% of patients had PDC â¥0.80."

Claims database • Clinical • Crohn's disease • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis

Safety of Inadvertent Live Vaccine Administration in Patients With Inflammatory Bowel Disease on Immune-Modifying Therapy (ACG 2026) - "The exposed cohort comprised IBD patients who received a live vaccine (measles, mumps, and rubella (MMR), varicella, measles, mumps, rubella, and varicella (MMRV)...Inclusion required a vaccine CPT code, â¥12 months of continuous enrollment prior to index date, an IBD diagnosis (â¥2 IBD-related outpatient visits), and a prescription for an immune-modifying therapy (anti-tumor necrosis factor (TNF), vedolizumab, ustekinumab, tofacitinib, upadacitinib, risankizumab, guselkumab, or mirikizumab) < 90 days of the index date...³Anti-TNF agents: infliximab, adalimumab, certolizumab, golimumab...6Immunomodulators: methotrexate, azathioprine, 6-mercaptopurine... 220 IBD patients met inclusion criteria for the live vaccine cohort (132 MMR, 73 varicella, 15 MMRV); 170 (77%) were on anti-TNF therapy and 30 (14%) on vedolizumab (Figure). The comparator group comprised 2,204 PCV13 recipients Table for baseline demographics. All-cause hospitalization or ED..."

Clinical • Gastroenterology • Gastrointestinal Disorder • Herpes Zoster • Immunology • Infectious Disease • Inflammation • Inflammatory Bowel Disease • Measles • Mumps • Pneumococcal Infections • Rubella • Varicella Zoster • IL23A

Risk of Incident Melanoma With TNF-Alpha Inhibitor Therapy in Inflammatory Bowel Disease: A Propensity-Matched Cohort Study (ACG 2026) - " Using the TriNetX U.S. Collaborative Network, we identified adults â¥18 years with IBD who initiated TNFi on or before February 7, 2024; controls initiated mesalamine or a non-TNFi biologic (ustekinumab, vedolizumab, risankizumab, mirikizumab, or guselkumab). Patients with prior melanoma or melanoma in situ; exposure to opposite-class advanced therapy, JAK inhibitors (tofacitinib, upadacitinib), thiopurines (azathioprine, mercaptopurine, thioguanine), or methotrexate before or within 5 years after index were excluded... In TNFi vs mesalamine, 21,848 matched pairs (mean age 38.9 ± 17.9 years; 51.1% female sex; 78.0% White) accrued mean follow-up of 2.5 years (median 3.0 years). There was no statistically significant difference in incident melanoma (0.10% vs 0.08%; OR 1.22, 95% CI 0.66â2.28; P=0.53) or composite outcome (0.11% each; OR 1.04, 0.59â1.82; P=0.89). Melanoma in situ alone was not separately reportable in this comparison due to small..."

Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Melanoma • Solid Tumor

Prevalence and Outcomes of Hormone Therapy Use Among Menopausal Women With Inflammatory Bowel Disease (ACG 2026) - "However, patients with CD prescribed systemic HT had higher oral prednisone use, while osteoporosis/fracture outcomes were lower among patients receiving systemic HT. Figure: 1-Systemic non-transdermal HRT included oral estradiol, conjugated estrogens, esterified estrogens, synthetic conjugated estrogens A and B, oral progesterone, oral medroxyprogesterone, conjugated estrogens/bazedoxifene (Duavee), estradiol acetate vaginal ring (Femring), and norethindrone acetate/ethinyl estradiol (Femhrt). 2-Systemic transdermal HRT included estradiol/norethindrone acetate transdermal patch (CombiPatch), estradiol/levonorgestrel transdermal patch (Climara Pro), estradiol transdermal patches (Alora, Climara, Dotti, Estraderm, Lyllana, Minivelle, Vivelle-Dot), estradiol transdermal gel (EstroGel, Divigel), and estradiol transdermal spray (Evamist). 3-Local estrogen therapy included low-dose vaginal estradiol formulations (Estring, Imvexxy, Vagifem, and Yuvafem) and vaginal conjugated..."

Clinical • Cardiovascular • Coronary Artery Disease • Crohn's disease • Gastroenterology • Gastrointestinal Disorder • Heart Failure • Hematological Disorders • Immunology • Inflammation • Inflammatory Bowel Disease • Musculoskeletal Diseases • Orthopedics • Osteoporosis • Pulmonary Embolism • Respiratory Diseases • Ulcerative Colitis

Dual Biologic Therapy in a Pregnant Patient With Crohn's Disease and Axial Spondyloarthritis (ACG 2026) - "She had previous non-response to mesalamine, mercaptopurine, certolizumab pegol, adalimumab, infliximab, and upadacitinib, as well as combination therapy with upadacitinib and vedolizumab. She then achieved clinical remission with a combination of risankizumab and golimumab...Recent randomized trials showed improved rates of clinical remission in patients with ulcerative colitis and Crohnâs disease treated with dual therapy with guselkumab and golimumab compared to monotherapy...Data from the Pregnancy Inflammatory bowel disease And Neonatal Outcomes (PIANO) registry has shown no increased risk of pregnancy complications in patients treated with anti-TNF medications, immunomodulators, TNF/immunomodulator combination therapy, vedolizumab, and ustekinumab in patients with IBD. This case highlights emerging therapeutic strategies and the importance of patient centered multidisciplinary care for optimal pregnancy outcomes."

Clinical • Ankylosing Spondylitis • Crohn's disease • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease • Seronegative Spondyloarthropathies • Spondylarthritis • Ulcerative Colitis • CRP